These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8493427)

  • 21. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of therapeutic research on informed consent and the ethics of clinical trials: a medical oncology perspective.
    Daugherty CK
    J Clin Oncol; 1999 May; 17(5):1601-17. PubMed ID: 10334550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On the development of the Medical Research Council trial of alpha-interferon in metastatic renal carcinoma. Urological Working Party Renal Carcinoma Subgroup.
    Fayers PM; Cook PA; Machin D; Donaldson N; Whitehead J; Ritchie A; Oliver RT; Yuen P
    Stat Med; 1994 Nov; 13(21):2249-60. PubMed ID: 7846423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of data monitoring committees in Canadian trial groups.
    Pater JL
    Stat Med; 1993 Mar; 12(5-6):505-8. PubMed ID: 8493428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Futility approaches to interim monitoring by data monitoring committees.
    Demets DL
    Clin Trials; 2006; 3(6):522-9. PubMed ID: 17170036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strength of accumulating evidence and data monitoring committee decision making.
    George SL; Freidlin B; Korn EL
    Stat Med; 2004 Sep; 23(17):2659-72. PubMed ID: 15316949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees.
    ; Dixon DO; Freedman RS; Herson J; Hughes M; Kim K; Silverman MH; Tangen CM
    Clin Trials; 2006; 3(3):314-9. PubMed ID: 16895048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of quality of life in clinical trials of the British Medical Research Council.
    Machin D
    J Natl Cancer Inst Monogr; 1996; (20):97-102. PubMed ID: 8750478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative.
    Calis KA; Archdeacon P; Bain R; DeMets D; Donohue M; Elzarrad MK; Forrest A; McEachern J; Pencina MJ; Perlmutter J; Lewis RJ
    Clin Trials; 2017 Aug; 14(4):342-348. PubMed ID: 28503947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Independence of the statistician who analyses unblinded data.
    Siegel JP; O'Neill RT; Temple R; Campbell G; Foulkes MA
    Stat Med; 2004 May; 23(10):1527-9. PubMed ID: 15122732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring of clinical trials and interim analyses from a drug sponsor's point of view.
    Williams GW; Davis RL; Getson AJ; Gould AL; Hwang IK; Matthews H; Shih WJ; Snapinn SM; Walton-Bowen KL
    Stat Med; 1993 Mar; 12(5-6):481-92. PubMed ID: 8493426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
    Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Issues in regulatory guidelines for data monitoring committees.
    DeMets D; Califf R; Dixon D; Ellenberg S; Fleming T; Held P; Julian D; Kaplan R; Levine R; Neaton J; Packer M; Pocock S; Rockhold F; Seto B; Siegel J; Snapinn S; Stump D; Temple R; Whitley R
    Clin Trials; 2004; 1(2):162-9. PubMed ID: 16281888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The size of clinical trials in cancer research--what are the current needs? Medical Research Council Cancer Therapy Committee.
    Freedman LS
    Br J Cancer; 1989 Mar; 59(3):396-400. PubMed ID: 2930705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding the functions and operations of data monitoring committees: Survey and focus group findings.
    Calis KA; Archdeacon P; Bain RP; Forrest A; Perlmutter J; DeMets DL
    Clin Trials; 2017 Feb; 14(1):59-66. PubMed ID: 27885056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Organization of multicenter clinical trials.
    Meinert CL
    Control Clin Trials; 1981 May; 1(4):305-12. PubMed ID: 7261620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Scientific review of EORTC trials: the functioning of the New Treatment Committee and Protocol Review Committee.
    Lardot C; Steward W; Van Glabbeke M; Armand JP
    Eur J Cancer; 2002 Mar; 38 Suppl 4():S24-30. PubMed ID: 11858960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What is the appropriate role of the trial statistician in preparing and presenting interim findings to an independent Data Monitoring Committee in the U.S. Cancer Cooperative Group setting?
    Bryant J
    Stat Med; 2004 May; 23(10):1507-11. PubMed ID: 15122728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proposal for ethical standards in therapeutic trials.
    Arpaillange P; Dion S; Mathe G
    Br Med J (Clin Res Ed); 1985 Sep; 291(6499):887-9. PubMed ID: 3931754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.